We serve Chemical Name:(E)-N-Methyl-1-(3-pyridinyl)methanimine CAS:16273-54-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(E)-N-Methyl-1-(3-pyridinyl)methanimine
CAS.NO:16273-54-4
Synonyms:N-(3-Pyridylmethyliden)methylamine;N-(Pyridin-3-ylmethylene)methanamine;N-(3-pyridylmethylene)methylamine;Pyridin-3-aldehyd-methylimin;(E)-N-(PYRIDIN-3-YLMETHYLENE)METHANAMINE;3-Pyridinemethanimine, α-methyl-;3-(N-Methylformimidoyl)pyridine;N-(3-Pyridylmethylidene)methylamine;N-[(E)-Pyridin-3-ylmethylene]methanamine;N-Methyl-N-(3-pyridylmethylene)amine;(E)-N-Methyl-1-(3-pyridinyl)methanimine;methanamine, N-[(1E)-3-pyridinylmethylene]-;methyl-pyridin-3-ylmethylene-amine;1-(3-Pyridinyl)ethanimine
Molecular Formula:C7H8N2
Molecular Weight:120.152
HS Code:2933399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:229.6±22.0 °C at 760 mmHg
Density:1.0±0.1 g/cm3
Index of Refraction:1.545
PSA:25.25000
Exact Mass:120.068748
LogP:-0.11
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like N-(3-Pyridylmethyliden)methylamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-(3-Pyridinyl)ethanimine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-(3-Pyridylmethyliden)methylamine Use and application,(E)-N-Methyl-1-(3-pyridinyl)methanimine technical grade,usp/ep/jp grade.
Related News: The pharmaceutical industry is related to the national economy and the people’s livelihood. The entire upstream and downstream areas involve all aspects of the national economy. Our government has a long-term direct or indirect policy preference for this. (E)-N-Methyl-1-(3-pyridinyl)methanimine manufacturer Inceptua has global operations with local offices across Europe, USA, and Asia (E)-N-Methyl-1-(3-pyridinyl)methanimine supplier One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. (E)-N-Methyl-1-(3-pyridinyl)methanimine vendor One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. (E)-N-Methyl-1-(3-pyridinyl)methanimine factory Inceptua has global operations with local offices across Europe, USA, and Asia
